Dashboard Tools Market News Investing Ideas Pricing
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
B

Bioretec Oy
F:0TN

Watchlist Manager
Bioretec Oy
F:0TN
Watchlist
Price: 0.0194 EUR Market Closed
Market Cap: €394.5k
Write Note Create Alert Ask AI

Wall St Price Targets

0TN Price Targets Summary
Bioretec Oy

Wall Street analysts forecast 0TN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for 0TN is 0.0247 EUR with a low forecast of 0.0245 EUR and a high forecast of 0.0255 EUR.

0TN Lowest Forecast
Wall Street Target
€0.0245
26% Upside
0TN Average Forecast
Wall Street Target
€0.0247
27% Upside
0TN Highest Forecast
Wall Street Target
€0.0255
31% Upside
Lowest Forecast
Price Target
0.0245 EUR
26% Upside
Average Forecast
Price Target
0.0247 EUR
27% Upside
Highest Forecast
Price Target
0.0255 EUR
31% Upside
Bioretec Oy Competitors:
Price Targets
RVSB
Riverview Bancorp Inc
31% Upside
A
ATC
Arctic Paper SA
57% Upside
S
SK
Sigdo Koppers SA
5% Upside
NESR
National Energy Services Reunited Corp
18% Upside
RVSB
Riverview Bancorp Inc
31% Upside
A
ATC
Arctic Paper SA
57% Upside
S
SK
Sigdo Koppers SA
5% Upside
NESR
National Energy Services Reunited Corp
18% Upside

Revenue
Forecast

12% / Year
Past Growth
52% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss
12% / Year
Past Growth
52% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Over the last 6 years, the compound annual growth rate for Revenue has been 12%. The projected CAGR for the next 3 years is 52%.

What are analyst estimates?

Gross Profit
Forecast

11% / Year
Past Growth
105% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss
11% / Year
Past Growth
105% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Over the last 6 years, the compound annual growth rate for Gross Profit has been 11%. The projected CAGR for the next 2 years is 105%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat

What are analyst estimates?

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
4%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
4%
Average Beat

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
2%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
2%
Average Beat

What are analyst estimates?

Continue 0TN Research

Summary
0TN intrinsic value, competitors valuation, and company profile.
DCF Valuation
0TN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
0TN stock valuation using valuation multiples.
Wall St Estimates
0TN price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
0TN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other Bioretec Oy listings:
OMXH • EUR
BRETEC
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is 0TN's stock price target?
Price Target
0.0247 EUR

According to Wall Street analysts, the average 1-year price target for 0TN is 0.0247 EUR with a low forecast of 0.0245 EUR and a high forecast of 0.0255 EUR.

What is the Revenue forecast for Bioretec Oy?
Projected CAGR
52%

Over the last 6 years, the compound annual growth rate for Revenue has been 12%. The projected CAGR for the next 3 years is 52%.

What is the Gross Profit forecast for Bioretec Oy?
Projected CAGR
105%

Over the last 6 years, the compound annual growth rate for Gross Profit has been 11%. The projected CAGR for the next 2 years is 105%.

Back to Top
ALPHA SPREAD
Follow us
Join 351,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett